<DOC>
	<DOCNO>NCT02079805</DOCNO>
	<brief_summary>Multicenter , randomize , open-label , parallel-group exploratory study explore effect azilsartan ( Azirva ) , compare telmisartan , insulin resistance patient essential hypertension complicate type 2 diabetes mellitus</brief_summary>
	<brief_title>A Study Explore Effects Azilsartan Compared Telmisartan Insulin Resistance Patients With Essential Hypertension Type 2 Diabetes Mellitus HOMA-R</brief_title>
	<detailed_description>The primary objective present study explore effect azilsartan 20 mg , compare telmisartan 40 mg , daily orally 12 week insulin resistance patient essential hypertension complicate type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . The participant give diagnosis grade I II essential hypertension judge principal investigator investigator appropriately treat azilsartan 20 mg telmisartan 40 mg. 2 . Sitting systolic blood pressure ≥ 130 mmHg &lt; 180 mmHg sit diastolic blood pressure ≥ 80 mmHg &lt; 110 mmHg start treatment period ( Week 0 ) Sitting blood pressure measure 2 consecutive stable measurement obtain ( i.e. , difference 2 measurement : diastolic blood pressure &lt; 5 mmHg systolic blood pressure &lt; 10 mmHg ) rest sit position least 5 minute . The average value last 2 measurement record ( first decimal place round ) . 3 . Type 2 diabetes mellitus 4 . HbA1c ( NGSP ( National Glycohemoglobin Standardization Program ) value ) &lt; 8.4 % 3 month inform consent , ≤ 0.3 % change HbA1c ( peak minus nadir ) 3 month inform consent 5 . No change diet/exercise therapy 3 month inform consent subject diet/exercise therapy instruct improve life style ( e.g. , diet exercise ) 6 . Age ≥ 20 year time consent 7 . Outpatients 8 . Capable provide write consent participation study . 1 . Grade III essential hypertension ( i.e. , sit systolic blood pressure 180 mmHg sit diastolic blood pressure ≥ 110 mmHg ) , secondary hypertension , malignant hypertension . 2 . Grade II essential hypertension ( i.e. , sit systolic blood pressure ≥ 160 mmHg sit diastolic blood pressure ≥ 100 mmHg ) antihypertensive drug ( ) use 3 . Use oral antihypertensive medication within 2 week start treatment period Participants antihypertensive agent time inform consent enrol study 2week washout follow informed consent . 4 . Use RAS inhibitor thiazolidines within 3 month start treatment period 5 . Type 1 diabetes mellitus 6 . Fasting blood glucose &lt; 180 mg/dL HOMAR ≤ 1.6 start treatment period ( Week 0 ) 7 . Receiving require follow time informed consent : Insulin , glucagonlike peptide1 ( GLP1 ) receptor agonist , parenteral hypoglycemic agent Combination therapy 3 oral hypoglycemic agent 8 . Change antidiabetic medication ( include dosage change ) within 3 month start treatment period 9 . Having diagnosed/treated follow cardiovascular disease within 3 month start treatment period : Cardiac disease/condition : myocardial infarction , coronary revascularization procedure Cerebrovascular disease : cerebral infarction , cerebral haemorrhage , transient ischaemic attack Advanced hypertensive retinopathy ( retinal bleeding oozing , papilloedema ) 10 . Having diagnosed/treated follow cardiovascular disease 3 month start treatment period , still unstable condition . Cardiac disease/condition : myocardial infarction , coronary revascularization procedure Cerebrovascular disease : cerebral infarction , cerebral haemorrhage , transient ischaemic attack 11 . Past current history follow cardiovascular disease . Cardiac valve stenosis Angina pectoris require medication Congestive cardiac failure require medication Arrhythmia require medication ( e.g. , paroxysmal atrial fibrillation , severe bradycardia , torsade de pointes , ventricular fibrillation ) Arteriosclerosis obliterans intermittent claudication symptom 12 . Have severe ketosis , diabetic coma precoma , severe infection , serious trauma 13 . Clinically evident renal disorder ( e.g. , eGFR &lt; 30 mL/min/1.73 m2 ) 14 . Markedly low bile secretion severe hepatic disorder 15 . History hypersensitivity allergy azilsartan telmisartan . 16 . Presence hyperkalemia ( potassium level ≥ 5.5 mEq/L laboratory test ) 17 . Currently participate clinical study . 18 . Pregnant woman , woman possible pregnancy , breastfeed woman . 19 . Other patient inappropriate participation study opinion principal investigator investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>